Outlook Therapeutics, Inc. logo

Outlook Therapeutics, Inc. (OTLK) Q1 2026 Earnings

OTLK·Reported May 15, 2026·Before market open

Outlook Therapeutics, Inc. reported Q1 2026 revenue of $128.0K, missed analyst consensus of $4.4M by $4.3M. Diluted EPS came in at $-0.16 (+60.0% YoY), missed the $-0.12 consensus by $0.04.

Revenue
$128.0Kmissed by $4.3M
Consensus: $4.4M
Diluted EPS
$-0.16missed by $0.04
Consensus: $-0.12
SEC

SEC Filings

Earnings release8-K · 0001104659-26-060305
Quarterly report10-Q · 0001104659-26-062632

Financial Snapshot

Trailing eight quarters through Q1 2026

View all metrics

Q1 2026 Earnings FAQ

Common questions about Outlook Therapeutics, Inc.'s Q1 2026 earnings report.

Outlook Therapeutics, Inc. (OTLK) reported Q1 2026 earnings on May 15, 2026 before market open.

Outlook Therapeutics, Inc. reported revenue of $128.0K and diluted EPS of $-0.16 for Q1 2026.

Revenue missed the consensus estimate of $4.4M by $4.3M. EPS missed the consensus estimate of $-0.12 by $0.04.

Compared to the same quarter a year prior, diluted EPS grew 60.0% from $-0.40.

You can read the 8-K earnings release (0001104659-26-060305) and the 10-Q periodic report (0001104659-26-062632) directly on SEC EDGAR. The filing index links above go to sec.gov.